Skin layer-specific Melan-A expression during progression of human cutaneous melanoma: Implications for diagnostic applications of the marker

Melanoma Research

Volumn 18, Issue 4, 2008, Pages 259-267

  Sztramska, Anna ^a   Dymerska, Dagmara ^a   Chwirot, Barbara W ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Cutaneous melanoma; Immunohistochemical marker; Melan A; Melanoma progression

Indexed keywords

MELAN A; BIOLOGICAL MARKER; MART1 ANTIGEN; TUMOR ANTIGEN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; MELANOMA CELL; NEVUS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUMOR GROWTH; IMMUNOLOGY; METABOLISM; PATHOLOGY; SKIN; SKIN TUMOR;

ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NEOPLASM PROTEINS; NEVUS; SENSITIVITY AND SPECIFICITY; SKIN; SKIN NEOPLASMS;

EID: 58149389585     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328303beac     Document Type: Article

References (54)

1. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007; 445:851-857.
2. Ackerman AB, Cerroni L, Kehrl H. Pitfalls in histopathologic diagnosis of malignant melanoma. Philadelphia, Baltimore, Hong Kong, London, Munich, Sydney, Tokyo: Lea & Febiger, A Waverly Co.; 1994.
3. Barrow C, Browning J, MacGregor D, Davis ID, Sturrock S, Jungbluth AA, et al. Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 2006; 12:764-771.
4. Berset M, Cerottini JP, Guggisberg D, Romero P, Burri F, Rimoldi D, et al. Expression of Melan-A/MART-1 antigen as a prognostic factor in primary cutaneous melanoma. Int J Cancer 2001; 95:73-77.
5. Mangini J, Li N, Bhawan J. Immunohistochemical markers of melanocytic lesions: a review of their diagnostic usefulness. Am J Dermatopathol 2002; 24:270-281.
6. Megahed M, Schon M, Selimovic D, Schon MP. Reliability of diagnosis of melanoma in situ. Lancet 2002; 359:1921-1922.
7. Orchard GE. Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma. Histochem J 2000; 32:475-481.
8. Blessing K, Sanders DS, Grant JJ. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology 1998; 32:139-146.
9. Clarkson KS, Sturdgess IC, Molyneux AJ. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol 2001; 54: 196-200.
10. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994; 180: 35-42.
11. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180:347-352.
12. Romero P, Valmori D, Pittet MJ, Zippelius A, Rimoldi D, Levy F, et al. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev 2002; 188:81-96.
13. Orosz Z. Melan-A/Mart-1 expression in various melanocytic lesions and in non-melanocytic soft tissue tumours. Histopathology 1999; 34: 517-525.
14. Sheffield MV, Yee H, Dorvault CC, Weilbaecher KN, Eltoum IA, Siegal GP, et al. Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations. Am J Clin Pathol 2002; 118:930-936.
15. Yaziji H, Gown AM. Immunohistochemical markers of melanocytic tumors. Int J Surg Pathol 2003; 11:11-15.
16. Crotty K, McCarthy S, Mihm M. The histological diagnosis and classification of melanoma. In: Thompson JF, Morton DL, Kroon BBR, editors. Textbook of melanoma. London, New York: Martin Dunitz, Taylor & Francis Group; 2004. pp. 115-128.
17. Jungbluth AA, Busam KJ, Gerald WL, Stockert E, Coplan KA, Iversen K, et al. A103: an anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Am J Surg Pathol 1998; 22:595-602.
18. L'Hostis H, Deminiere C, Ferriere JM, Coindre JM. Renal angiomyolipoma: a clinicopathologic, immunohistochemical, and follow-up study of 46 cases. Am J Surg Pathol 1999; 23:1011-1020.
19. El Shabrawi-Caelen L, Kerl H, Cerroni L. Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis. Am J Dermatopathol 2004; 26:364-366.
20. Evans MJ, Sanders DS, Grant JH, Blessing K. Expression of Melan-A in Spitz, pigmented spindle cell nevi, and congenital nevi: comparative immunohistochemical study. Pediatr Dev Pathol 2000; 3:36-39.
21. Maize JC Jr, Resneck JS Jr, Shapiro PE, McCalmont TH, LeBoit PE. Ducking stray 'magic bullets': a Melan-A alert. Am J Dermatopathol 2003; 25:162-165.
22. Kageshita T, Kawakami Y, Hirai S, Ono T. Differential expression of MART-1 in primary and metastatic melanoma lesions. J Immunother 1997; 20: 460-465.
23. Xu X, Chu AY, Pasha TL, Elder DE, Zhang PJ. Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas. Am J Surg Pathol 2002; 26:82-87.
24. Kucher C, Zhang PJ, Pasha T, Elenitsas R, Wu H, Ming ME, et al. Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic nevi. Am J Dermatopathol 2004; 26:452-457.
25. Kim YC, Lee MG, Choe SW, Lee MC, Chung HG, Cho SH. Acral lentiginous melanoma: an immunohistochemical study of 20 cases. Int J Dermatol 2003; 42:123-129.
26. Dean NR, Brennan J, Haynes J, Goddard C, Cooter RD. Immunohistochemical labeling of normal melanocytes. Appl Immunohistochem Mol Morphol 2002; 10:199-204.
27. Frohlich E, Mack AF, Garbe C, Klessen C. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas. Br J Dermatol 2005; 153:1159-1165.
28. Yu CH, Chen HH, Liu CM, Jeng YM, Wang JT, Wang YP, et al. HMB-45 may be a more sensitive maker than S-100 or Melan-A for immunohistochemical diagnosis of primary oral and nasal mucosal melanomas. J Oral Pathol Med 2005; 34:540-545.
29. Fernandes BF, Odashiro AN, Saraiva VS, Logan P, Antecka E, Burnier MN Jr. Immunohistochemical expression of melan-A and tyrosinase in uveal melanoma. J Carcinog 2007; 6:6.
30. De Vries TJ, Smeets M, de Graaf R, Hou-Jensen K, Brocker EB, Renard N, et al. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group. J Pathol 2001; 193:13-20.
31. Murer K, Urosevic M, Willers J, Selvam P, Laine E, Burg G, et al. Expression of Melan-A/MART-1 in primary melanoma cell cultures has prognostic implication in metastatic melanoma patients. Melanoma Res 2004; 14:257-262.
32. Hochberg M, Lotem M, Gimon Z, Shiloni E, Enk CD. Expression of tyrosinase, MIA and MART-1 in sentinel lymph nodes of patients with malignant melanoma. Br J Dermatol 2002; 146:244-249.
33. Mahmood MN, Lee MW, Linden MD, Nathanson SD, Hornyak TJ, Zarbo RJ. Diagnostic value of HMB-45 and anti-Melan A staining of sentinel lymph nodes with isolated positive cells. Mod Pathol 2002; 15: 1288-1293.
34. Gajjar NA, Cochran AJ, Binder SW. Is MAGE-1 expression in metastatic malignant melanomas really helpful? Am J Surg Pathol 2004; 28:883-888.
35. Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 2005; 102:6092-6097.
36. Gao Z, Stanek A, Chen S. A metastatic melanoma with an unusual immunophenotypic profile. Am J Dermatopathol 2007; 29:169-171.
37. Seftor EA, Brown KM, Chin L, Kirschmann DA, Wheaton WW, Protopopov A, et al. Epigenetic transdifferentiation of normal melanocytes by a metastatic melanoma microenvironment. Cancer Res. 2005; 62: 1847-1853.
38. Haass NK, Smalley KS, Li L, Herlyn M. Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res 2005; 18:150-159.
39. Hsu MY, Meier F, Herlyn M. Melanoma development and progression: a conspiracy between tumor and host. Differentiation 2002; 70: 522-536.
40. Postovit LM, Seftor EA, Seftor RE, Hendrix MJ. Influence of the microenvironment on melanoma cell fate determination and phenotype. Cancer Res 2006; 66:7833-7836.
41. Reinke S, Koniger P, Herberth G, Audring H, Wang H, Ma J, et al. Differential expression of MART-1, tyrosinase, and SM5-1 in primary and metastatic melanoma. Am J Dermatopathol 2005; 27:401-406.
42. Zubovits J, Buzney E, Yu L, Duncan LM. HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma. Hum Pathol 2004; 35:217-223.
43. Fetsch PA, Steinberg SM, Riker AI, Marincola FM, Abati A. Melanoma antigen expression in serial fine-needle aspiration samples in patients with metastatic malignant melanoma participating in immunotherapy clinical trials: a preliminary look. Cancer 2001; 93:409-414.
44. Heegaard S, Jensen OA, Prause JU. Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea: comparison of the novel antibody against melan-A with S100 protein and HMB-45. Melanoma Res 2000; 10:350-354.
45. Hofbauer GF, Boni R, Simmen D, Mihic D, Nestle FO, Burg G, et al. Histological, immunological and molecular features of a nasal mucosa primary melanoma associated with nasal melanosis. Melanoma Res 2002; 12:77-82.
46. Magro CM, Crowson AN, Mihm MC. Unusual variants of malignant melanoma. Mod Pathol 2006; 19 (Suppl 2):S41-S70.
47. Ruiter DJ, Mooi WJ, van Muijen GN, Cochran AJ. Immunohistochemistry and special diagnostic techniques. In: Thompson JF, Morton DL, Kroon BBR, editors. Textbook of melanoma. London, New York: Martin Dunitz, Taylor & Francis Group; 2004. pp. 129-147.
48. Benlalam H, Vignard V, Khammari A, Bonnin A, Godet Y, Pandolfino MC, et al. Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients. Cancer Immunol Immunother 2007; 56:515-526.
49. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo N et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997; 3:37-44.
50. Jaeger E, Bernhard H, Romero P, Ringhoffer M, Arand M, Karbach J, et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 1996; 66: 162-169.
51. Jager E, Maeurer M, Hohn H, Karbach J, Jager D, Zidianakis Z, et al. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int J Cancer 2000; 86:538-547.
52. Speiser DE, Cerottini JC, Romero P. Tumor cell recognition efficiency by T cells. PLoS Med 2005; 2:e77; author reply e95.
53. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003; 3:411-421.
54. Bortheiry AL, Malerbi DA, Franco LJ. The ROC curve in the evaluation of fasting capillary blood glucose as a screening test for diabetes and IGT. Diabetes Care 1994; 17:1269-1272.